May 8, 2023 07:10 AM EDTUpdated May 12, 12:27 PM
People
Bioregnum

Re­mem­ber that record biotech IPO par­ty in 2018? There was no ‘hap­pi­ly ever af­ter’

Back in the sum­mer of 2018, Aptinyx $AP­TX was bud­ding with high hopes. Its pre­de­ces­sor com­pa­ny, Nau­rex, had sold to Al­ler­gan so Brent Saun­ders and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times